Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Musa Yılmaz et al.|New England Journal of Medicine|2019Cited by 502
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D. DiNardo, Hagop M. Kantarjian, Curtis A. Lachowiez et al.|Journal of Clinical Oncology|2021Cited by 333
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Marina Konopleva, Abhishek Maiti et al.|Cancer|2021Cited by 156
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activationYasmin Abaza, Guillermo Garcia‐Manero, Juliana E. Hidalgo‐Lόpez et al.|Leukemia Research|2018Cited by 9